P&G OTC sales up 2%, paced by Pepto, Metamucil, but offset by 6% oral care sales drop.
This article was originally published in The Tan Sheet
Executive Summary
P&G PEPTO-BISMOL, METAMUCIL DRIVE 2% OTC VOLUME GROWTH in North America for the company's second quarter of FY 1998 (ended Dec. 31), Procter & Gamble Assistant Treasurer James Prevost told securities analysts during a Jan. 27 conference call. However, total health care volume dropped 2% because a 6% decline in oral care products sales was only partially offset by gains in sales of OTCs such as the Vicks line of cough/cold products, Pepto and Metamucil, Prevost noted.